AstraZeneca (AZN): news on Monday 12 October 2026

The 8 stories

Each headline's own score, strongest first. Links go to the publisher.

• −7.5 AstraZeneca Efzimfotase Alfa Misses Primary Endpoint in HPP Trial Securities.io
  Efzimfotase alfa missed primary endpoint in HPP trial.
• −6.7 AstraZeneca announces ALXN1850 did not achieve statistical significance TipRanks
  Trial of ALXN1850 missed statistical significance.
• +5.0 AstraZeneca (LSE:AZN) AI Drug Discovery Push Keeps The Undervalued Narrative In Play Simply Wall Street
  AI drug discovery push framed as undervalued narrative.
• +5.0 Summit secures $2 billion AstraZeneca investment The Business Journals
  Large $2 billion investment in Summit supports oncology pipeline.
• +4.2 Weekly Recap: U.S. $50B expansion and Summit stake funding ivonescimab TradingView
  US expansion and Summit stake funding ivonescimab development.
• +2.5 AstraZeneca Young Health Programme and UNICEF partner to advance health equity in Thailand Bangkok Post
  Positive community health partnership, minor reputational boost.}
• +1.7 Astrazeneca Says Efzimfotase Alfa Shows Improvement In Primary And Key Secondary Endpoints At Week 25 And Week 49 TradingView
  Company framing mixed results, some improvement at weeks 25 and 49.
• +0.8 Efzimfotase alfa showed numerical improvement in Six-Minute Walk Test achieving mean difference of 17.05 meters vs placebo in treatment-naïve adolescents and adults with hypophosphatasia at week 25 in HICKORY Phase III trial AstraZeneca US
  Numerical improvement reported, but not clearly decisive.